on the treatment of RM-NPC with camrelizumab found that ORR was 28.2% and mPFS was 3.7 months.(20) Our study, which included both PD-L1-positive and PD-L1-negative patients, demonstrated that the ORR was significantly higher than that for immunotherapy alone, and the mPFS was prolonged. The gene discussed is CD274; the disease is nasopharyngeal carcinoma.